The stock rose to $ 60.60 in Wednesday’s extended trade after a previous jump of 7%. Data from the Phase 1 trial of the possible coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with the University of Oxford, will be published Monday, according to the Lancet medical journal.
The data is expected to demonstrate whether the potential vaccine is safe and whether or not it triggers an immune response. Earlier this month, vaccine developers said they were encouraged by the immune response they’ve seen in trials so far.
“We hope that this document, which is in the process of being edited and finally prepared, will be published on Monday July 20 for immediate publication,” a magazine spokeswoman told Reuters.
Meanwhile, the vaccine candidate is already in large-scale phase III human trials to assess whether he can protect against COVID-19.
AstraZeneca has signed supply chain agreements in recent weeks for the ability to produce 2 billion doses of its candidate vaccine. The British pharmacist has signed supply agreements with the countries of the United States and the European Union.
AZD1222 is one of several candidates endorsed by Operation Warp Speed (OWS), the US government’s program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines available to Americans in January 2021.
Shares have risen 53% since mid-March when AstraZeneca joined the list of companies involved in developing a possible coronavirus vaccine. Despite the recent recovery, the average analyst price target of $ 61.67 still puts the upside potential at 6.3% in the next 12 months. (See analysis of actions of AstraZeneca in TipRanks)
Overall, the stock gains a Strong Buy consensus from the analyst community based on 4 unanimous Buy ratings.
Latest articles from Smarter Analyst:
